| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Longeveron GAAP EPS of -$1.91 misses by $0.21, revenue of $0.12M misses by $0.68M | 1 | Seeking Alpha | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| Do | Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update | 1 | GlobeNewswire (USA) | ||
| Do | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
| Do | Longeveron Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.10. | Longeveron Announces Engagement of Lucid Capital Markets | 2 | GlobeNewswire (USA) | ||
| 26.10. | Longeveron Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 26.10. | Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) | 6 | GlobeNewswire (USA) | ||
| 14.10. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.09. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.09. | Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value? | 1 | Insider Monkey | ||
| 17.09. | Morning Market Movers: Aethlon Medical, CID HoldCo, Longeveron, Delixy See Big Swings | 949 | AFX News | OTTAWA (dpa-AFX) - At 8:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 17.09. | Longeveron's phase 2b stem cell flop spurs cost cutting, exploration of 'all options' | 12 | FierceBiotech | ||
| 17.09. | Longeveron (LGVN) Shares Slide 59% After Hours: Here's Why | 5 | Benzinga.com | ||
| 16.09. | Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) | 256 | GlobeNewswire (Europe) | Company Announces Exploration of All Options to Maximize Shareholder Value The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular... ► Artikel lesen | |
| 14.09. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 24.08. | Longeveron plans 1-for-10 reverse stock split to regain Nasdaq minimum bid-price compliance | 1 | Seeking Alpha | ||
| 24.08. | Longeveron Announces 1-for-10 Reverse Stock Split | 454 | GlobeNewswire (Europe) | MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related... ► Artikel lesen | |
| 19.08. | Nirav Jhaveri wird neuer CFO bei Longeveron | 1 | Investing.com Deutsch | ||
| 19.08. | Longeveron Inc. - 8-K, Current Report | 4 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 57,50 | +0,88 % | Christian Koch, Leiter BB Biotech Team bei Bellevue Asset Management, im Interview | von Robert Jakob Moneycab.com: Herr Koch, acht bestehende Beteiligungen verkauft, zwölf neue Positionen aufgebaut, das sieht nach einer grösseren Rochade aus? Die Veränderungen spiegeln unser aktives... ► Artikel lesen | |
| VALNEVA | 2,492 | -3,45 % | Valneva-Aktie über der 50-Tage-Linie: Positive Shigella-Daten treiben an | ||
| EPIGENOMICS | 0,870 | 0,00 % | PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
Epigenomics AG: Veröffentlichung nach -- 40 Abs. 1 WpHG
Heidelberg (pta000/26.10.2026/15:00... ► Artikel lesen | |
| NOVAVAX | 7,210 | -0,28 % | Novavax: Warum der Zahlen-Erfolg nicht alle überzeugt | ||
| BIOFRONTERA | 2,960 | +1,02 % | Biofrontera AG: Liquidität unter Druck - was jetzt zählt | ||
| HEIDELBERG PHARMA | 2,090 | +2,45 % | Formycon gegen Heidelberg Pharma gegen Medios: Das Biotech-Nebenwert-Duell - Medios liegt beim Chance-Risiko vorn | ||
| CRISPR THERAPEUTICS | 38,090 | +4,46 % | 99 Millionen Dollar mit neuer Gentherapie: Vertex und CRISPR Therapeutics legen zu - Mesoblast wächst um 44 Prozent | ||
| PALATIN TECHNOLOGIES | 5,260 | -1,87 % | Palatin targets phase I start in first half of calendar 2027 for lead MC4R lipidated peptide | ||
| BIOXXMED | 0,800 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 30.10.2026 | The following instruments on XETRA do have their last trading day on 30.10.2026Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 30.10.2026ISIN NameDE000A41YD32 BIOXXMED AG INH O.N.DE000HLB78G8... ► Artikel lesen | |
| OCUGEN | 0,698 | +1,60 % | Ocugen: Lizenzdeal mit Celairis - OCU400 bekommt Asien-Pazifik-Schub | ||
| INOVIO PHARMACEUTICALS | 1,490 | +0,27 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| CLINUVEL | 4,359 | -1,51 % | CLINUVEL PHARMACEUTICALS LIMITED: Change in substantial holding - Updated | ||
| BAVARIAN NORDIC | 32,700 | +1,81 % | Bavarian Nordic A/S: Bavarian Nordic Reports Strong Travel Health Growth in the Third Quarter and Confirms Solid Momentum for the Rest of the Year | COPENHAGEN, Denmark, November 13, 2026 - Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the third quarter and first nine months of 2026.
Financial... ► Artikel lesen | |
| EDITAS MEDICINE | 1,650 | -0,60 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 0,636 | -8,36 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen |